Invasive candidiasis (IC; candidemia and other deep-seated infections, including disseminated candidiasis, endocarditis, meningitis, and hepatosplenic infection) now is widely recognized as an important public health problem, with considerable morbidity, mortality, and associated health care costs (1, 6, 11, 14, 17, 19, 23, 36, 44) . Although much of the literature concerning IC has focused on nosocomial (NOS) bloodstream infections (BSI), especially those occurring in the intensive care unit (ICU) (3, 12, 13, 25, 27, 49) , an increasing incidence of IC overall (35, 50) , combined with data from the National Nosocomial Infection System survey, which found a decline in the frequency of candidemia among ICU patients in the United States (47) , suggest that the burden of IC is shifting from the ICU to other health care settings. Hajjeh et al. (17) have shown that in 1998 through 2000, only 36% of Candida BSIs occurred in the ICU, whereas 28% were community onset (CO), an increase of almost 10% above that reported in 1992 and 1994 (19) . Subsequently, Sofair et al. (45) determined that 31% of 1,143 cases of candidemia were CO infections (occurring Յ2 days after hospital admission). These observations led participants in a recent health care-associated (HCA) infection summit to conclude that clinicians should be aware of the potential for Candida to be a cause of BSI in patients presenting to the emergency department (20) .
Recently, Shorr et al. (42) found that CO candidemia represented a distinct clinical entity with substantial morbidity and mortality. Compared to other types (bacterial) of CO BSIs, patients with CO candidemia were more severely ill and likely to have been recently discharged from an acute-care hospital or admitted from another health care facility or nursing home (42) . Thus, candidemia has spread beyond the confines of acute-care hospitals, and the failure to consider CO candidemia in at-risk subjects may have adverse consequences (42) .
There now are several candidemia surveys that have provided estimates of the frequency of CO compared to that of nosocomial cases in different geographic locations (1, 6, 10, 11, 17, 19, 22, 26, 32, 38, 41, 45, 48) ; however, very few have examined the distribution of species in these two settings, and none provide data concerning the resistance profiles of CO versus nosocomial isolates to the available systemically active antifungal agents.
The SENTRY Antimicrobial Surveillance Program (antifungal objective), active since 1997, has reported previously that 25% of candidemia episodes (1, 184 ) from an international survey in 1997-1999 were nonnosocomial or CO (38) . In the present study, we update this landmark information using the SENTRY program database from 2008-2009, including geo-
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Frequency of CO candidemia in three geographic regions. Among the 1,354 episodes of candidemia, 494 (36.5%) were CO and 860 (63.5%) were nosocomial ( Table 1) . The frequency of CO candidemias was considerably higher in North America (50.8%) than that observed in Europe (22.4%) and Latin America (28.0%). In each region, however, the frequency of CO candidemia increased from 2008 to 2009 (data not shown).
These data may be compared to that of 12 different surveys spanning the last 17 years and covering several different geographic settings (Table 2 ). Whereas some of these studies identified CA and HCA BSIs, most used the definition for CO defined for the present study, without the differentiation of CA and HCA. Those who identified CA, HCA, and nosocomial BSIs found that patients presenting with HCA BSI were similar to those with nosocomial infections, whereas those with CA infections included patients with intravenous drug use, gastrointestinal disorders, and diabetes (6) . Although the SENTRY program does not collect clinical or risk factor data, we assume that the vast majority of the CO BSI patients in this survey have HCA risk factors.
Although the variation in the frequency of CO candidemia was considerable (Table 2) , most of these studies reported that greater than 10% of Candida BSI may be categorized as CO, with the highest proportions being detected in the United States. Within the United States, it is notable that the CO candidemia frequency has increased from 16 to 20% in 1992-1993 (19, 48) , to 31% in 1998-2000 (45) , and to 50.8% in the present study. Whereas the latter figure seems high, the trend in the United States is unmistakable and supports the concerns voiced by Kollef et al. (20) and Shorr et al. (42) .
As cost containment pressures continue to mount and hospital discharges to secondary-care facilities (including home care) are expedited, clearly the boundaries between nosocomial and CO infection may no longer be valid (9, 10, 18, 24, 42, 43) . In the United States, increasing numbers of patients are being managed in the community with risk-increasing proce- In analyzing the frequency of the isolation of different species by CO and nosocomial BSI, we found only minor differences (Table 3) . C. albicans was more common among CO infections, while C. parapsilosis and C. krusei were more common among nosocomial candidemias. Most of the other surveys where pathogen distribution was reported showed that C. albicans was more common in nosocomial BSI and that C. parapsilosis was more common in CO infections (Table 3) . Although it has been speculated that the prominence of C. parapsilosis as a cause of candidemia in CO infections is due to the exogenous introduction of this skin commensal into the bloodstream via long-term vascular catheters, there is little objective evidence to support this hypothesis (6, 45) .
Differences in antifungal agent susceptibilities among isolates from CO and nosocomial BSIs. As shown in Table 4 , no resistance to anidulafungin, caspofungin, micafungin, posaconazole, or voriconazole was detected among CO isolates of C. albicans, C. parapsilosis, C. tropicalis, or C. krusei. In fact, the only resistance to fluconazole detected in these four species was observed in isolates of C. parapsilosis. Among CO isolates of C. glabrata, resistance to anidulafungin, caspofungin, and all three triazoles was found in a small number of isolates.
Among the nosocomial isolates of C. albicans, one isolate (from a patient in Germany) was resistant to all three echinocandins, whereas no resistance to the azoles was detected. None of the nosocomial isolates of C. parapsilosis or C. tropicalis were resistant to the echinocandins; however, 5.8% of the a Resistance defined as a MIC of Ͼ0.5 g/ml for anidulafungin, caspofungin, and micafungin against C. albicans, C. tropicalis, and C. krusei and as a MIC of Ͼ4 g/ml for C. parapsilosis; resistance defined as a MIC of Ͼ0.5 g/ml for anidulafungin and caspofungin and as a MIC of Ͼ0.12 g/ml for micafungin against C. glabrata; resistance defined as a MIC Ͼ4 g/ml for fluconazole against C. albicans, C. tropicalis, and C. parapsilosis, and as a MIC of Ͼ32 g/ml for posaconazole and voriconazole against all species.
b Total number of isolates tested. (30) . This recommendation may inadvertently result in increased drug pressure on C. parapsilosis, with a subsequent increase in azole resistance. Thus, fluconazole resistance among C. parapsilosis isolates must be recognized as a possibility, and this species should be monitored closely in the future. Cross-resistance between fluconazole and voriconazole was noted in 2.2% of C. tropicalis isolates of nosocomial origin. Overall, fluconazole resistance was observed in 2.6% of CO isolates but 5.8% of nosocomial isolates. Along these lines, it should be noted that C. parapsilosis and C. tropicalis accounted for 29% of all fluconazole resistance in this survey. Resistance was infrequent among nosocomial isolates of C. krusei, where only two isolates resistant to caspofungin were detected. Resistance to both azoles and echinocandins was most prominent in C. glabrata isolates, with the highest resistance rates to anidulafungin (3.8%), caspofungin (5.1%), micafungin (3.2%), fluconazole (7.7%), posaconazole (5.1%), and voriconazole (6.4%) found in the isolates of nosocomial origin (Table  4) . A total of 12 nosocomial isolates of C. glabrata (caspofungin MIC, Ն0.5 g/ml) were selected to be tested for the presence of fks mutations; five were classified as intermediate (MIC, 0.5 g/ml), and several were classified as resistant (MIC, Ն1 g/ ml) to caspofungin. None of the isolates for which the caspofungin MIC was 0.5 g/ml contained an fks mutation, while six of the seven resistant isolates were shown to have a mutation in either fks1 or fks2 (Table 5 ). Of the six isolates shown to have fks mutations, five were categorized as resistant and one as intermediate to anidulafungin and micafungin (Table 5) , confirming the utility of the resistant CBP.
Other investigators have noted the propensity of C. glabrata to mutate to a multidrug-resistant (MDR) phenotype in vivo in a single patient (5, 21) and have suggested that the expression of resistance to echinocandins and other classes of antifungal agents in C. glabrata is facilitated by the haploid nature of the genome (5, 40). Our observations support the potential emergence of an MDR phenotype among nosocomial isolates of C. glabrata with cross-resistance in azole and echinocandin classes. The fear of azole resistance and the generally excellent wild-type susceptibility of most species of Candida to the echinocandins has driven the use of echinocandins for the treatment of IC (30) . The increase of MDR C. glabrata strains has become a serious concern expressed by several investigators (5, 40, 46) , and it argues for continued close resistance surveillance and the increased application of standardized antifungal susceptibility testing.
The increasing recognition of CO candidemia raises the issue of whether an antifungal therapy should be added to the first-line empirical antimicrobial regimen for patients presenting with sepsis (9, 20, 42, 45) . It is now evident that a delay in initiating antifungal therapy in the critically ill patient is associated with compromised outcomes (an increase in mortality of 8% for each hour in which appropriate therapy is delayed), excessive costs of hospitalization, and potentially devastating complications such as endocarditis, endophthalmitis, osteomyelitis, and disseminated candidiasis (2, 15, 16, 23, 29, 31, 42) . Shorr et al. (42) demonstrated that the risk-adjusted mortality rate (28.3%), length of stay in hospital (13.7 days), and attributable cost ($30,219 per episode) was greater for CO candidemia patients than that for patients with CO bacteremia. Ideally the decision to initiate antifungal therapy should be guided by rapid diagnostic markers and/or risk stratification schema to maximize benefits and reduce the risk of drug toxicity and resistance development (9, 20) . In the absence of such diagnostic aids, it seems reasonable to consider treating highrisk patients with clinical evidence of sepsis with an antifungal agent with systemic activity against Candida spp. This would be especially true if the patient was known to be colonized with a yeast (9, 20, 42) . The lack of resistance to both the echinocandins and azoles among CO candidemia isolates shown in the present study suggests that at least for now, such decisions may be made without fear of resistance.
There are several notable findings in this survey of contemporary CO and nosocomial Candida BSI isolates. First, it is evident that CO candidemias are not rare and appear to be increasing worldwide due to changes in health care practices. Second, whereas the species distribution is similar between CO and nosocomial BSI, resistance to the azoles and echinocandins is quite uncommon among CO isolates. Third, the frequency of azole resistance among CO and nosocomial isolates of C. parapsilosis is important and bears watching. Fourth, the finding of both azole and echinocandin resistance in nosocomial isolates of C. glabrata is very disturbing and indicates that this species will continue to pose a major therapeutic problem even in the current echinocandin era. These findings argue for increased awareness of CO candidemia as a distinct clinical entity that appears to be becoming more common throughout the world. An increased level of suspicion and the prompt application of appropriate systemically active antifungal therapy, coupled with timely and accurate identification and antifungal susceptibility testing, will be necessary to optimize the management of this important infectious process. Being a descriptive and sentinel-based survey, there are certain limitations inherent in the SENTRY surveillance program that must be acknowledged. The lack of clinical data, severity of illness measures, risk factors, and antifungal drug exposure limits the clinical utility of this study. Despite a long-standing protocol for testing and reporting consecutive isolates from individual infectious episodes and the collection of a necessarily limited amount of demographic information, there are no controls for participant compliance with the isolate submission and completion of the demographic data forms from one year to the next. Despite these limitations, the overall size of the data set presented herein does provide useful descriptive information. Such information will continue to be useful as a basis for future studies regarding the prevalence of CO candidemia and antifungal susceptibility of associated species as agents of invasive candidiasis throughout the world.
